João Conde, leader of the Cancer NanoMedicine lab at CEDOC, is one of the contributors of a new The Lancet publication on Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019.
This work comes from the Global Burden of Disease (GBD) consortium, which provides a tool to quantify health loss from hundreds of diseases, injuries, and risk factors, so that health systems can be
improved and disparities can be eliminated. The GBD is the most comprehensive effort to date to measure epidemiological levels and trends worldwide. The flexible design of the GBD machinery allows for regular updates as new data and epidemiological studies are made available.
The role of CEDOC and the Cancer NanoMedicine lab as a research group that works in new therapies for cancer is to evaluate the estimates and numbers of prevalence and mortality rates for the oncology panel of the GBD consortium. In this study João and the rest of the consortium evaluated the prevalence of such disease in child under-5 and neonates, from 2000-2019.
"After being invited by the GBD consortium, the privilege to take part of such important studies that calculate the global burden of diseases like cancer is overwhelming and with such a great benefit for the work we do, every day", said João about this effort.
You can check the full article here.
Map of individual countries' progress toward achieving the Sustainable Development Goals 3.2 target of reducing neonatal mortality rate to the threshold of 12 neonatal deaths per 1000 livebirths
João Conde Photo by André Luís Alves